Comparative analyses of mechanistic differences among antiestrogens

Endocrinology

Volumn 140, Issue 12, 1999, Pages 5828-5840

  Wijayaratne, Ashini L ^a   Nagel, Susan C ^a   Paige, Lisa A ^b   Christensen, Dale J ^b   Norris, John D ^a   Fowlkes, Dana M ^b   McDonnell, Donald P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Novalon Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GW 7604; IDOXIFENE; LIGAND; RALOXIFENE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY;

EID: 0033305525     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.12.7164     Document Type: Article

References (49)

1. Cardiovascular disease in women
2. The effect of postmenopausal estrogen therapy on bone density in elderly women
3. Insights from the study of animals lacking functional estrogen receptor
4. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
5. ERβ Identification and Characterization of a novel human estrogen receptor
6. Generation and reproductive phenotypes of mice lacking estrogen receptor β
7. Steroid receptors and their associated proteins
8. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
9. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain
10. The N-terminal region of the chicken progesterone receptor Specifies target gene activation
11. Functional dissection of the yeast Cyc8-Tupl transcriptional co-repressor complex
12. Menopausal estrogen replacement therapy and breast cancer
13. Phase II study of tamoxifen: Report of 74 patients with stage IV breast cancer
14. Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival
15. Endocrine effects of adjuvant chemo-therapy and long-term tamoxifen administration on node-positive patients with breast cancer
16. Response to a specific antiestrogen (ICI182,780) in tamoxifen-resistent breast cancer
17. Estrogen agonist-antagonist
18. Estrogen receptor mutations in breast cancer
19. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells
20. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
21. Identification of a new subclass of alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers
22. A simple, rapid and sensitive DNA assay procedure
23. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol
24. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity
25. Estrogen receptor modulators each induce distinct conformational changes in ERα and ERβ
26. Rapid test for in vivo stability and DNA binding of mutated octamer binding proteins with 'mini-extracts' prepared from transfected cells
27. Sensitivity and insensitivity of breast cancer to tamoxifen
28. Steroidal pure antioestrogens
29. The binding of drugs by plasma proteins
30. The interaction of drugs and plasma protein
31. Moecular basis of agonism and antagonism in the oestrogen receptor
32. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
33. Agonist and antagonist properties of RU486 on the functions of the human progesterone receptor
34. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen
35. Antiestrogen ICI164,384 reduces cellular estrogen receptor content by increasing its turnover
36. Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors
37. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
38. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology
39. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator
40. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
41. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
42. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
43. 16a-substituted anologs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting m mixed agonist activity
44. The nuclear corepressors NCoR and SMRT are key regulators of both ligand and 8-bromo-cAMP dependent transcriptional activity of the human progesterone receptor
45. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of ER in bone
46. The estrogen antagonist ICI182,780 reduces cancellous bone volume in female rats